title: Defining the molecular landscape of ependymomas.
abstract: Ependymomas have a variable prognosis. In this issue of Cancer Cell, Pajtler and colleagues identify nine subgroups of ependymoma using DNA methylation profiles. Two subgroups, predominately pediatric, are responsible for most of the mortality, with all others having nearly 100% overall survival after 5 years.
authors.affiliation: Department of Neurology, Boston Children's Hospital, Harvard Medical School, Harvard University, Cambridge, MA 02138, USA; Broad Institute of MIT and Harvard, Harvard University, Cambridge, MA 02138, USA.
authors.forename: Tenley C
authors.initials: TC
authors.lastname: Archer
authors.affiliation: Department of Neurology, Boston Children's Hospital, Harvard Medical School, Harvard University, Cambridge, MA 02138, USA; Broad Institute of MIT and Harvard, Harvard University, Cambridge, MA 02138, USA. Electronic address: scott.pomeroy@childrens.harvard.edu.
authors.forename: Scott L
authors.initials: SL
authors.lastname: Pomeroy
mesh_terms: D000367:Age Factors; D016543:Central Nervous System Neoplasms / Q000473:pathology*; D004806:Ependymoma / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male